Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jingjing, Zhang, Mingzhi, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784459/
https://www.ncbi.nlm.nih.gov/pubmed/26957112
http://dx.doi.org/10.1186/s13045-016-0250-9
_version_ 1782420270948024320
author Wu, Jingjing
Zhang, Mingzhi
Liu, Delong
author_facet Wu, Jingjing
Zhang, Mingzhi
Liu, Delong
author_sort Wu, Jingjing
collection PubMed
description More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s macroglobulinemia. More selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored. Acalabrutinib (ACP-196) is a novel irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib. This review summarized the preclinical research and clinical data of acalabrutinib.
format Online
Article
Text
id pubmed-4784459
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47844592016-03-10 Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor Wu, Jingjing Zhang, Mingzhi Liu, Delong J Hematol Oncol Review More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s macroglobulinemia. More selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored. Acalabrutinib (ACP-196) is a novel irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib. This review summarized the preclinical research and clinical data of acalabrutinib. BioMed Central 2016-03-09 /pmc/articles/PMC4784459/ /pubmed/26957112 http://dx.doi.org/10.1186/s13045-016-0250-9 Text en © Wu et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Wu, Jingjing
Zhang, Mingzhi
Liu, Delong
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
title Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
title_full Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
title_fullStr Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
title_full_unstemmed Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
title_short Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
title_sort acalabrutinib (acp-196): a selective second-generation btk inhibitor
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784459/
https://www.ncbi.nlm.nih.gov/pubmed/26957112
http://dx.doi.org/10.1186/s13045-016-0250-9
work_keys_str_mv AT wujingjing acalabrutinibacp196aselectivesecondgenerationbtkinhibitor
AT zhangmingzhi acalabrutinibacp196aselectivesecondgenerationbtkinhibitor
AT liudelong acalabrutinibacp196aselectivesecondgenerationbtkinhibitor

Ejemplares similares